Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2021-06-18. The firm provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
Follow-Up Questions
Who is the CEO of Telesis Bio Inc?
Mr. Eric Esser is the President of Telesis Bio Inc, joining the firm since 2022.
What is the price performance of TBIO stock?
The current price of TBIO is $0.001, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Telesis Bio Inc?
Telesis Bio Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Telesis Bio Inc market cap?
Telesis Bio Inc's current market cap is $1780
Is Telesis Bio Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Telesis Bio Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
